Paolo Tarantino: Precision medicine for HR+ metastatic breast cancer: from hope to reality in little more than 5 years

Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared on LinkedIn:

“Precision medicine for HR+ metastatic breast cancer: from hope to reality in little more than 5 years.

2018: first PARP inhibitors (olaparib and talazoparib)
2019: first PI3K inhibitor (alpelisib)
2022 first ADC for HR+ disease (T-DXd)
2023 first oral SERD for ESR1-mutant cancers (elacestrant) and first AKT inhibitor (capivasertib) and  second ADC (SG)
2024 first triplet for PIK3CA-mutant tumors (inavolisib triplet)

A honor to have the chance to review this evolving landscape with my mentor Sara Tolaney at the 6th PER Precision Medicine Symposium.”

Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.